S&P Futures
4,134.00 -13.75 (-0.33%) Dow Futures
33,886.00 -76.00 (-0.22%) Nasdaq Futures
12,573.25 -50.75 (-0.40%) Russell 2000 Futures
1,984.70 -8.80 (-0.44%) Crude Oil
73.51 +0.12 (+0.16%) Gold
1,889.70 +13.10 (+0.70%)
INOVIO PHARMACEUTICAL INC (GBMB.DU)
Chart Events
Performance Outlook
| Previous Close | 1.5914 |
| Open | 1.5928 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 1.5836 - 1.7646 |
| 52 Week Range | 1.2960 - 3.5925 |
| Volume | |
| Avg. Volume | 8 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").
- PR Newswire
INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo. In the trial, INO-4201 was well-tolerated and boosted humoral responses in 100% (36 of 36) of tr
- PR Newswire
INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced a strategic reorganization that is intended to deliver on commitments to operational efficiency and better position the company to bring the promise of DNA medicines to patients. The reorganization is expected to provide annual savings of approximately $4.3 million and includes an 11% r
